Formed by the reaction of elemental gallium with nitric acid; alters the mineral, matrix, and cellular properties of bone. Prepn: A. Dupré, C. R. Hebd. Seances Acad. Sci. 86, 720 (1878); of octahydrate: E. Einecke, Angew. Chem. 55, 40 (1942); of nonahydrate: R. Reinmann, A. Tanner, Z. Naturforsch. 20b, 71 (1965). Toxicity and antitumor activity: M. M. Hart et al., J. Natl. Cancer Inst. 47, 1121 (1971). Clinical pharmacokinetics: D. P. Kelsen et al., Cancer 46, 2009 (1980). Clinical trial in Paget's disease: R. S. Bockman et al., J. Clin. Endocrinol. Metab. 80, 595 (1995). Review of properties and clinical development: B. J. Foster et al., Cancer Treat. Rep. 70, 1311-1319 (1986); of clinical studies in treatment of bone metastases: R. P. Warrell, Jr., Cancer 80, 1680-1685 (1997); of therapeutic uses: G. Apseloff, Am. J. Ther. 6, 327-339 (1999). Series of articles on pharmacology and mechanism of action: Semin. Oncol. 18, Suppl. 5, 1-31 (1991); on clinical experience in multiple myeloma, lymphoma, bladder cancer and cancer-related hypercalcemia: ibid. 30, Suppl. 5, 1-41 (2003).
Antineoplastic; antipagetic; bone resorption inhibitor.
Antineoplastic; Antipagetic; Bone Resorption Inhibitor